| Features: Bacteria | ||||||||||||||||||||||||||||||||||||||||||
| Akkermansia improves cancer immunotherapy. Gram-negative anaerobic bacterium of the phylum Verrucomicrobia. Akkermansia muciniphila is a typical member of the human gut microbiome. Akkermansia — a gut-resident, Gram-negative, obligate anaerobic bacterium (phylum Verrucomicrobia), most commonly referring to Akkermansia muciniphila, a mucin-degrading keystone member of the human intestinal microbiome. It is best classified as a microbiome agent (commensal taxon; “next-generation probiotic” / live biotherapeutic concept, strain-dependent), commonly abbreviated Akk or A. muciniphila. In oncology, Akkermansia is primarily positioned as a predictive biomarker and a mechanistic adjunct for immune checkpoint inhibitor (ICI) responsiveness rather than a cytotoxic drug, with multiple human cohorts linking baseline abundance to improved anti–PD-1/PD-L1 outcomes and early-stage clinical development of strain-specific products. Primary mechanisms (ranked):
Bioavailability / PK relevance: Not a systemically distributed small molecule; exposure is primarily intraluminal (colon) with host effects mediated by epithelial/immune sensing and downstream systemic immune-metabolic signaling. Translation is strain-, viability-, formulation-, and colonization-dependent; “pasteurized” (non-viable) preparations can retain bioactivity for some non-oncology endpoints. In-vitro vs systemic exposure relevance: Not concentration-driven in plasma; mechanistic claims should be interpreted through ecological/host-response readouts (engraftment, relative abundance, metabolomics, immune phenotyping) rather than micromolar cellular dosing. Clinical evidence status: Human evidence is strongest for association/prediction of ICI benefit (observational cohorts, including prospective validation) and for feasibility/safety in non-cancer metabolic trials; interventional oncology evidence is emerging (early-phase live biotherapeutic/oncobiotic studies and microbiome modulation strategies), not an approved cancer therapy. Summary:-Can significantly inhibit carcinogenesis and improve anti-tumor effects, thus increasing the effectiveness of cancer immunotherapy. -Enhanced abundance of Akkermansia in the intestine of those who responded positively to the ICI(immune checkpoint inhibitors). -plausible general guidance: Eat fermented foods then fibre to maintain them. Fruits and vegs for fibre Chicory root for fibre (inulin which is main prebiotic). • Akkermansia muciniphila specializes in degrading mucin, the glycoprotein component of the mucus layer lining the gut. • Early clinical findings suggest that higher levels of Akkermansia correlate with improved responses to immune checkpoint inhibitors in cancer therapy.(e.g., anti-PD-1/PD-L1 therapy). Akkermansia, and in particular Akkermansia muciniphila, is a key gut bacterium implicated in supporting intestinal health, modulating immune responses, and influencing metabolic balance. Its roles in enhancing gut barrier integrity, reducing inflammation, and possibly improving responses to cancer immunotherapy make it an attractive target for probiotic development and microbiome-based interventions. Although not a drug in itself, Akkermansia’s potential as a biomarker and therapeutic adjunct offers promising avenues for integrative approaches in precision medicine and cancer care. Mechanistic axes for Akkermansia relevant to cancer translation
|
| Source: |
| Type: protein |
| PD-1 (Programmed Death-1) is a protein that plays a crucial role in the immune system's ability to fight cancer. It is a checkpoint protein that helps regulate the immune response by preventing the immune system from attacking healthy cells. PD-1 is often exploited by cancer cells to evade the immune system. Cancer cells can produce proteins that bind to PD-1, inhibiting the immune response and allowing the cancer cells to grow and proliferate unchecked. However, researchers have discovered that blocking the PD-1 pathway can help restore the immune system's ability to fight cancer. This has led to the development of PD-1 inhibitors, a class of cancer therapies that target the PD-1 protein. PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype. PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers). |
| 541- | Akk, | Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes? |
| - | Review, | NA, | NA |
| 542- | Akk, | immuno, | Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:26 Target#:709 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid